HUP0400477A3 - Compounds and methods for treatment and diagnosis of chlamydial infection - Google Patents

Compounds and methods for treatment and diagnosis of chlamydial infection

Info

Publication number
HUP0400477A3
HUP0400477A3 HU0400477A HUP0400477A HUP0400477A3 HU P0400477 A3 HUP0400477 A3 HU P0400477A3 HU 0400477 A HU0400477 A HU 0400477A HU P0400477 A HUP0400477 A HU P0400477A HU P0400477 A3 HUP0400477 A3 HU P0400477A3
Authority
HU
Hungary
Prior art keywords
diagnosis
compounds
treatment
methods
chlamydial infection
Prior art date
Application number
HU0400477A
Other languages
English (en)
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/620,412 external-priority patent/US6448234B1/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of HUP0400477A2 publication Critical patent/HUP0400477A2/hu
Publication of HUP0400477A3 publication Critical patent/HUP0400477A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4648—Bacterial antigens
    • A61K39/464835—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HU0400477A 2000-07-20 2001-07-20 Compounds and methods for treatment and diagnosis of chlamydial infection HUP0400477A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/620,412 US6448234B1 (en) 1998-12-08 2000-07-20 Compounds and methods for treatment and diagnosis of chlamydial infection
US09/841,132 US20020061848A1 (en) 2000-07-20 2001-04-23 Compounds and methods for treatment and diagnosis of chlamydial infection
PCT/US2001/023121 WO2002008267A2 (en) 2000-07-20 2001-07-20 Compounds and methods for treatment and diagnosis of chlamydial infection

Publications (2)

Publication Number Publication Date
HUP0400477A2 HUP0400477A2 (hu) 2004-05-28
HUP0400477A3 true HUP0400477A3 (en) 2010-01-28

Family

ID=27088713

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400477A HUP0400477A3 (en) 2000-07-20 2001-07-20 Compounds and methods for treatment and diagnosis of chlamydial infection

Country Status (25)

Country Link
US (9) US20020061848A1 (hu)
EP (1) EP1307564B1 (hu)
JP (1) JP2004513622A (hu)
KR (1) KR20030016423A (hu)
CN (1) CN100467600C (hu)
AT (1) ATE373092T1 (hu)
AU (2) AU8070201A (hu)
BR (1) BR0112602A (hu)
CA (1) CA2418282A1 (hu)
CY (1) CY1107796T1 (hu)
CZ (1) CZ2003480A3 (hu)
DE (1) DE60130468T2 (hu)
DK (1) DK1307564T3 (hu)
ES (1) ES2294018T3 (hu)
HK (1) HK1067381A1 (hu)
HU (1) HUP0400477A3 (hu)
IL (2) IL153904A0 (hu)
MX (1) MXPA03000564A (hu)
NO (1) NO20030252L (hu)
NZ (3) NZ541013A (hu)
PL (1) PL209107B1 (hu)
PT (1) PT1307564E (hu)
RU (2) RU2410394C2 (hu)
WO (1) WO2002008267A2 (hu)
ZA (1) ZA200300719B (hu)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629167A (en) * 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
WO2000011180A1 (en) 1998-08-20 2000-03-02 Connaught Laboratories Limited NUCLEIC ACID MOLECULES ENCODING POMP91A PROTEIN OF $i(CHLAMYDIA)
WO2000011181A1 (en) 1998-08-20 2000-03-02 Connaught Laboratories Limited NUCLEIC ACID MOLECULES ENCODING INCLUSION MEMBRANE PROTEIN C OF $i(CHLAMYDIA)
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020094340A1 (en) 1998-12-01 2002-07-18 Andrew D. Murdin Chlamydia antigens and corresponding dna thereof
EP1144642B1 (en) 1998-12-08 2010-05-26 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6555115B1 (en) * 1998-12-08 2003-04-29 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20080213264A1 (en) * 1998-12-08 2008-09-04 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
CA2356057A1 (en) 1998-12-28 2000-07-06 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
MXPA01009256A (es) 1999-03-12 2003-07-14 Aventis Pasteur Antigenos de chlamydia y fragmentos de acido desoxirribonucleico correspondientes y usos de los mismos.
CA2373021A1 (en) 1999-05-03 2000-11-09 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
DE60037900T2 (de) 1999-09-20 2009-02-12 Sanofi Pasteur Ltd., Toronto Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
CA2395499C (en) 1999-12-22 2011-10-25 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
CA2407114A1 (en) 2000-04-21 2001-11-01 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
AU2001258105A1 (en) 2000-05-08 2001-11-20 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
JP2004502415A (ja) 2000-07-03 2004-01-29 カイロン　エセ．ピー．アー． Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅに対する免疫化
US7731980B2 (en) * 2000-10-02 2010-06-08 Emergent Product Development Gaithersburg Inc. Chlamydia PMP proteins, gene sequences and uses thereof
US7537772B1 (en) 2000-10-02 2009-05-26 Emergent Product Development Gaithersburg Inc. Chlamydia protein, gene sequence and the uses thereof
US20030059896A1 (en) * 2000-12-21 2003-03-27 Shire Biochem Inc. Novel chlamydia antigens and corresponding DNA fragments
GB2370838A (en) * 2001-01-06 2002-07-10 Benedikt Timmerman Immunogenic complex
ATE406912T1 (de) 2001-12-12 2008-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia tracheomatis
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
CN1812809A (zh) * 2003-06-26 2006-08-02 希龙公司 用于沙眼衣原体的免疫原性组合物
EP1689867A4 (en) * 2003-11-20 2007-08-22 Sanofi Pasteur Ltd IMMUNIZATION AGAINST CHLAMYDIA INFECTIONS
US8541007B2 (en) 2005-03-31 2013-09-24 Glaxosmithkline Biologicals S.A. Vaccines against chlamydial infection
EA201001322A1 (ru) * 2005-03-31 2011-02-28 Глаксосмитклайн Байолоджикалс С.А. Вакцины против хламидиоза
AU2006259858A1 (en) * 2005-05-12 2006-12-28 Novartis Vaccines And Diagnostics S.R.L. Immunogenic compositions for Chlamydia trachomatis
WO2007030879A1 (en) * 2005-09-13 2007-03-22 Diatech Pty Ltd Diagnostic markers and uses therefor
EP1981905B1 (en) * 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
EP1970708A1 (de) * 2007-03-07 2008-09-17 Mikrogen Molekularbiologische Entwicklungs-GmbH Biochip und Verfahren zum selektiven Nachweis von Chlamydia trachomatis-Infektionen
US20100310593A1 (en) * 2007-06-14 2010-12-09 Emergent Product Development Gaithersburg Inc. Vaccines Against Chlamydia Infection
AU2008284352A1 (en) * 2007-08-03 2009-02-12 President And Fellows Of Harvard College Chlamydia antigens
EP2722056A1 (en) * 2007-12-03 2014-04-23 President and Fellows of Harvard College CT062, a Chlamydia antigen
RU2011140508A (ru) 2009-03-06 2013-04-20 Новартис Аг Антигены хламидии
US9458513B2 (en) 2010-03-23 2016-10-04 Wako Pure Chemical Industries, Ltd. Primer and probe for detecting chlamydia trachomatis, and method for detecting chlamydia trachomatis using same
JP2013545448A (ja) * 2010-10-20 2013-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド クラミジア抗原及びその使用
US20130095487A1 (en) * 2011-10-18 2013-04-18 University Of South Florida Interferon-Gamma Response as a Diagnostic Test for Persistent Chlamydial Infections
US9481714B2 (en) * 2012-12-05 2016-11-01 Thevax Genetics Vaccine Co., Ltd. Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses
CN113801191B (zh) * 2021-08-18 2022-05-17 南京大学 一种检测衣原体的多肽探针及其应用

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4118469A (en) * 1976-04-27 1978-10-03 Research Corporation Antigen for trachoma lymphogranuloma venereum (LGV) and non-gonococcal urethritis (NGU)
US4497899A (en) * 1982-04-12 1985-02-05 Abbott Laboratories Immunoassay for Chlamydia trachomatis antigens
US4497900A (en) 1982-04-12 1985-02-05 Abbott Laboratories Immunoassay for Neisseria gonorrhoeae antigens
US4497863A (en) * 1984-03-07 1985-02-05 Milliken Research Corporation Laminated weft insertion fabric
EP0192033B1 (en) 1985-01-14 1996-09-25 Chiron Corporation Chlamydia major outer membrane protein
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
EP0348725A3 (en) 1988-06-29 1990-10-24 Miles Inc. Species-specific epitode of chlamydia trachomatis and antibodies that recognize the same
EP0628570A1 (en) * 1989-02-17 1994-12-14 Chiron Mimotopes Pty. Ltd. Method for the use and synthesis of peptides
US5869608A (en) * 1989-03-17 1999-02-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis
US5166053A (en) * 1990-02-23 1992-11-24 Miles Inc. Specimen adequacy control for chlamydia assays
JP3018553B2 (ja) * 1990-05-08 2000-03-13 日立化成工業株式会社 クラミジア・トラコマティス抗体測定方法及びクラミジア・トラコマティス感染症診断用製剤
US5725863A (en) 1991-09-06 1998-03-10 The United States Of America As Represented By The Secretary Of Agriculture Polypeptides useful in prevention of chlamydia infection
SG90042A1 (en) 1992-06-25 2002-07-23 Smithkline Beecham Biolog Vaccine composition containing adjuvants
EP0662083A1 (en) 1992-09-18 1995-07-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Synthetic peptide vaccine for chlamydia trachomatis
US5549978A (en) * 1992-10-30 1996-08-27 Kabushiki Kaisha Toshiba Magnetoresistance effect element
US5629167A (en) * 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
CN100365017C (zh) 1994-09-20 2008-01-30 日立化成工业株式会社 肺炎衣原体抗原多肽
GB9506863D0 (en) * 1995-04-03 1995-05-24 Smithkline Beecham Biolog Vaccines
GB9626864D0 (en) 1996-12-24 1997-02-12 Smithkline Beecham Biolog Vaccine
GB9516293D0 (en) 1995-08-09 1995-10-11 Immunova Ltee Novel peptides and their use as vaccines
CN1223589A (zh) * 1996-05-06 1999-07-21 美国拜尔公司 包含鹦鹉热衣原体的猫疫苗及其制备方法
BR9712971A (pt) 1996-07-12 2002-05-07 Univ Manitoba Método para produção de uma vacina para proteção de um hospedeiro contra doença causada com uma cadeia de chlamydia e composição imunológica
US6464979B1 (en) 1996-09-12 2002-10-15 Aventis Pasteur Limited Chlamydial vaccines and methods of preparation thereof
US7459524B1 (en) * 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
JP4249279B2 (ja) 1997-10-22 2009-04-02 デンカ生研株式会社 クラミジア・トラコマティス主要外膜蛋白質及びその製造方法、並びにクラミジア・トラコマティスの抗体測定方法及び抗体測定試薬
ATE480625T1 (de) * 1997-11-21 2010-09-15 Merck Serono Biodevelopment Äusseres membranpolypeptid von chlamydia pneumoniae sowie fragmente davon und deren verwendung, insbesondere zur diagnose, prävention und behandlung einer infektion
JP2002536958A (ja) 1997-11-21 2002-11-05 ジェンセット Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅゲノム配列およびポリペプチド、それらのフラグメント、ならびに特に感染症の診断、予防および治療のためのそれらの使用
US7041490B1 (en) * 1997-11-28 2006-05-09 Serono Genetics Institute, S.A. Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same
KR100769103B1 (ko) * 1997-11-28 2007-10-23 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
CN1163602C (zh) 1998-04-07 2004-08-25 科里克萨公司 结核杆菌抗原融合蛋白及其应用
WO2000023105A2 (en) * 1998-10-16 2000-04-27 Smithkline Beecham Biologicals S.A. Adjuvant systems and vaccines
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
EP1133572A4 (en) 1998-11-12 2005-06-15 Univ California GENOME SEQUENCE OF CHLAMYDIA PNEUMONIAE
US20080213264A1 (en) 1998-12-08 2008-09-04 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP1144642B1 (en) * 1998-12-08 2010-05-26 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6432916B1 (en) * 1998-12-08 2002-08-13 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6565856B1 (en) * 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6447779B1 (en) * 1998-12-08 2002-09-10 Corixa Corporation Compounds for the diagnosis of Chlamydial infection
US6166177A (en) * 1998-12-08 2000-12-26 Corixa Corporation Compounds and methods for the treatment and diagnosis of chlamydial infection
US6555115B1 (en) * 1998-12-08 2003-04-29 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6448234B1 (en) * 1998-12-08 2002-09-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
MXPA01009256A (es) 1999-03-12 2003-07-14 Aventis Pasteur Antigenos de chlamydia y fragmentos de acido desoxirribonucleico correspondientes y usos de los mismos.
CA2373021A1 (en) 1999-05-03 2000-11-09 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6811783B1 (en) 1999-09-07 2004-11-02 Aventis Pasteur Limited Immunogenic compositions for protection against chlamydial infection
DE60037900T2 (de) 1999-09-20 2009-02-12 Sanofi Pasteur Ltd., Toronto Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
CA2906516C (en) 1999-09-28 2017-03-07 Geneohm Sciences Canada Inc. Nucleic acids and methods for the detection of streptococcus
WO2001040757A2 (en) * 1999-10-14 2001-06-07 University Of Utah Research Foundation Resonant optical cavities for high-sensitivity, high-throughput biological sensors and methods
WO2001035992A1 (en) 1999-11-19 2001-05-25 Michigan State University Recombinant chlamydia vaccine
CA2395499C (en) 1999-12-22 2011-10-25 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US20010048927A1 (en) * 2000-02-01 2001-12-06 Richard Stephens Porin B (PorB) as a therapeutic target for prevention and treatment of infection by chlamydia
US20020146776A1 (en) * 2000-04-21 2002-10-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
CA2407114A1 (en) * 2000-04-21 2001-11-01 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
AU2001258105A1 (en) 2000-05-08 2001-11-20 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
EP1290720A1 (en) * 2000-06-16 2003-03-12 Applied Materials, Inc. Configurable single substrate wet-dry integrated cluster cleaner
JP2004502415A (ja) 2000-07-03 2004-01-29 カイロン　エセ．ピー．アー． Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅに対する免疫化
EP1301726A1 (de) * 2000-07-20 2003-04-16 ZF FRIEDRICHSHAFEN Aktiengesellschaft Elektromagnetisch betätigbare, schleifringlose einflächen-reibungskupplung
US7537772B1 (en) 2000-10-02 2009-05-26 Emergent Product Development Gaithersburg Inc. Chlamydia protein, gene sequence and the uses thereof
US7731980B2 (en) 2000-10-02 2010-06-08 Emergent Product Development Gaithersburg Inc. Chlamydia PMP proteins, gene sequences and uses thereof
GB0103169D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2002077183A2 (en) * 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
WO2002079244A2 (en) 2001-03-30 2002-10-10 University Of Manitoba Chlamydial protease-like activity factor responsible for degradation of host transcription factor
US20030199438A1 (en) * 2001-04-09 2003-10-23 Shaw Allan Christian Method for identification of proteins from intracellular bacteria
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
ATE406912T1 (de) * 2001-12-12 2008-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia tracheomatis
US7105171B2 (en) * 2002-03-07 2006-09-12 The Regents Of The University Of California Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
CN1812809A (zh) * 2003-06-26 2006-08-02 希龙公司 用于沙眼衣原体的免疫原性组合物
FR2869057B1 (fr) * 2004-04-16 2006-06-02 Piscines Desjoyaux Sa Sa Dispositif pour la realisation d'un haut de chainage d'un escalier
PT1812058E (pt) 2004-10-25 2012-09-17 Statens Seruminstitut Antigénios de chlamydia trachomatis para vacina e utilização em diagnóstico
US8541007B2 (en) * 2005-03-31 2013-09-24 Glaxosmithkline Biologicals S.A. Vaccines against chlamydial infection
EA201001322A1 (ru) * 2005-03-31 2011-02-28 Глаксосмитклайн Байолоджикалс С.А. Вакцины против хламидиоза
AU2006259858A1 (en) * 2005-05-12 2006-12-28 Novartis Vaccines And Diagnostics S.R.L. Immunogenic compositions for Chlamydia trachomatis
WO2007110700A2 (en) * 2005-12-22 2007-10-04 Novartis Vaccines And Diagnostics, Srl. Chlamydial antigens
EP1981905B1 (en) * 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
US20080124338A1 (en) * 2006-09-22 2008-05-29 The Scripps Research Institute Methods for treatment of inflammatory disease and chlamydia infectious disease
AU2007304199A1 (en) 2006-10-04 2008-04-10 Corixa Corporation Vaccines against Chlamydial infection
US7892567B2 (en) * 2007-10-01 2011-02-22 Board Of Regents, The University Of Texas System Methods and compositions for immunization against chlamydial infection and disease
JP2012505212A (ja) * 2008-10-09 2012-03-01 ボード・オヴ・リージェンツ，ユニヴァーシティ・オヴ・テキサス・システム クラミジア感染および疾患の診断および治療のためのクラミジア抗原に関する方法および組成物
US20110293664A1 (en) * 2008-12-17 2011-12-01 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
RU2011140508A (ru) * 2009-03-06 2013-04-20 Новартис Аг Антигены хламидии
EP2544715A2 (en) * 2010-03-09 2013-01-16 Board Of Regents, University Of Texas System Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease

Also Published As

Publication number Publication date
NO20030252L (no) 2003-03-14
NZ549873A (en) 2008-06-30
US20080299142A1 (en) 2008-12-04
PL365951A1 (en) 2005-01-24
US20120114684A1 (en) 2012-05-10
WO2002008267A2 (en) 2002-01-31
EP1307564B1 (en) 2007-09-12
CN1489628A (zh) 2004-04-14
NO20030252D0 (no) 2003-01-17
CY1107796T1 (el) 2013-06-19
NZ541013A (en) 2007-05-31
US20020061848A1 (en) 2002-05-23
AU2001280702B8 (en) 2008-02-28
IL153904A0 (en) 2003-07-31
US20080181918A1 (en) 2008-07-31
US20040234536A1 (en) 2004-11-25
US20110142872A1 (en) 2011-06-16
RU2410394C2 (ru) 2011-01-27
US8263089B2 (en) 2012-09-11
ES2294018T3 (es) 2008-04-01
US20080317772A1 (en) 2008-12-25
RU2003104976A (ru) 2004-07-10
CZ2003480A3 (cs) 2003-09-17
CN100467600C (zh) 2009-03-11
WO2002008267A3 (en) 2003-02-27
ZA200300719B (en) 2004-10-27
PL209107B1 (pl) 2011-07-29
JP2004513622A (ja) 2004-05-13
US8052975B2 (en) 2011-11-08
DK1307564T3 (da) 2007-12-27
HUP0400477A2 (hu) 2004-05-28
WO2002008267A9 (en) 2006-09-28
IL153904A (en) 2010-04-29
BR0112602A (pt) 2004-02-17
US7462357B2 (en) 2008-12-09
MXPA03000564A (es) 2004-12-13
AU8070201A (en) 2002-02-05
US20090035296A1 (en) 2009-02-05
EP1307564A2 (en) 2003-05-07
CA2418282A1 (en) 2002-01-31
HK1067381A1 (en) 2005-04-08
PT1307564E (pt) 2007-11-21
RU2006120003A (ru) 2007-12-27
DE60130468T2 (de) 2008-04-03
ATE373092T1 (de) 2007-09-15
AU2001280702B9 (en) 2002-02-05
NZ523628A (en) 2005-08-26
AU2001280702B2 (en) 2008-01-24
US20090028887A1 (en) 2009-01-29
KR20030016423A (ko) 2003-02-26
DE60130468D1 (de) 2007-10-25

Similar Documents

Publication Publication Date Title
HUP0400477A3 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
PL355977A1 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
AU2001280702A1 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
HUP0400719A3 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
AU6159901A (en) Surface treatment of medical device
HUP0302556A3 (en) Use of bisphosphonates for pain treatment
IL152553A0 (en) Compounds and methods for the treatment and prevention of bacterial infection
GB0015745D0 (en) Treatment of bone diseases
AU2002367535A8 (en) Diagnosis and treatment of vascular disease
IL145282A0 (en) Compositions and methods for treatment of staphylococcal infection
GB0020351D0 (en) Treatment of hyperproliferative diseases
GB0023915D0 (en) Treatment of neuroinflammatory disease
EP1351699A4 (en) METHOD FOR IMPROVED DIAGNOSIS AND TREATMENT OF MYCOBACTERIAL INFECTIONS
AU2001259507A1 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
AU2002220257A1 (en) Methods of treatment involving human mda-7
GB2360453B (en) Treatment of skin conditions
IL155819A0 (en) Methods of treatment comprising administration of substance p
IL154011A0 (en) Treatment of wounds
AU2002249891A1 (en) Compounds and methods for the diagnosis and treatment of babesia infection
GB9906808D0 (en) Formulation for treatment of pain
AU2002363638A1 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
EP1303281A4 (en) METHODS OF TREATMENT
AU2001261416A1 (en) Compounds and methods for the diagnosis and treatment of babesia microti infection
TW488455U (en) Improved cotton ball for medical treatment
GB0022210D0 (en) Treatment of infection in animals

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: CORIXA CORPORATION, US

Free format text: FORMER OWNER(S): CORIXA CORPORATION, US

FD9A Lapse of provisional protection due to non-payment of fees